AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $562.74M
• Dividend Yield: N/A
• Average Volume (3M): 477.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 304.17%
• EPS Growth: 29.37%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.34
• Shares Outstanding: 27,996,964
• 10 Day Avg. Volume: 441,536
• 30 Day Avg. Volume: 477,686
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.28
• Enterprise Value/Revenue: 5.85
• Enterprise Value/Gross Profit: 5.91
• Enterprise Value/Ebitda: -10.82
• 1Y Price Target: $48.70
• Price Target Upside: 143.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 40 Underperform
• Price Target: $19.50 ▼(-2.30% Downside)

AnaptysBio's overall stock score is primarily impacted by its financial instability, characterized by persistent net losses and negative equity. Technical analysis indicates bearish momentum, further weighing on the score. While the company has reported positive clinical trial results, the financial and technical challenges overshadow these developments, resulting in a low overall score.

Positive Factors

Commercial Performance of Jemperli

GSK announced strong commercial performance for Jemperli, with momentum suggesting it will exceed $1B in 2025 and generate a $75M milestone to ANAB.

Efficacy and Durability of Rosnilimab

Rosnilimab demonstrated strong efficacy and durability across both biologic-naïve and experienced populations in rheumatoid arthritis.

Stock Valuation

Shares are trading at a large discount.

Negative Factors

Concerns on UC Trial Outcome

Disappointing UC results for competitor JNJ’s PD-1 agonist JNJ-67484703 raise questions about rosnilimab’s Ph2b UC readout, although JNJ's data in RA appears weaker cross-trial relative to rosnilimab.

Market Competition

JNJ's drug appears flawed relative to rosnilimab, with discouraging results in ulcerative colitis trials.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

How the Company Makes Money

AnaptysBio generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies. The company enters into strategic alliances that often involve upfront payments, milestone payments contingent on the achievement of specific development goals, and royalties on future product sales. Additionally, AnaptysBio may receive funding for research and development activities as part of these collaborations. This model allows the company to monetize its innovative antibody platform and pipeline candidates while sharing the financial risks associated with drug development. As of now, the company has not yet commercialized any products, so its revenue is largely dependent on these partnerships and potential future royalties.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio is experiencing strong revenue growth but faces significant profitability and cash flow challenges. Despite increased revenue, the company remains unprofitable with negative margins and returns. The balance sheet shows moderate leverage and low equity levels, indicating a need to enhance profitability and cash flow.

Income Statement

AnaptysBio has experienced substantial revenue growth from $10.3M in 2022 to $111.9M TTM, indicating a strong upward trajectory. However, the company continues to operate at a loss, with a negative net profit margin of -125.7% and a negative EBIT margin of -89.7% TTM. This suggests significant profitability challenges despite revenue growth.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio of 0.46 TTM, indicating moderate leverage. The equity ratio stands at 8.1% TTM, reflecting a relatively low proportion of equity financing. The negative ROE of -413.2% TTM points to ongoing profitability issues impacting shareholder returns.

Cash Flow

AnaptysBio's free cash flow improved slightly from -$135.7M in 2024 to -$102.2M TTM, but remains negative, indicating cash flow challenges. The operating cash flow to net income ratio of 0.72 TTM shows that cash losses are closely aligned with accounting losses, highlighting limited cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	123.16M	91.28M	17.16M	10.29M	63.17M	75.00M
Gross Profit	121.97M	91.28M	14.78M	7.95M	-35.32M	-5.03M
EBITDA	-66.55M	-92.74M	-143.16M	-105.26M	-55.71M	-19.37M
Net Income	-132.59M	-145.23M	-163.62M	-128.72M	-57.19M	-19.92M
Balance Sheet
Total Assets	335.25M	483.83M	452.39M	610.38M	643.07M	416.55M
Cash, Cash Equivalents and Short-Term Investments	265.71M	385.37M	390.90M	441.24M	548.10M	393.65M
Total Debt	346.46M	16.04M	17.81M	19.45M	20.95M	342.00K
Total Liabilities	379.98M	412.97M	364.29M	348.28M	286.64M	19.82M
Stockholders Equity	-44.73M	70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow
Free Cash Flow	-128.08M	-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
Operating Cash Flow	-127.71M	-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
Investing Cash Flow	80.47M	95.40M	144.75M	-394.85M	38.84M	94.47M
Financing Cash Flow	19.71M	127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 19.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Negative. The current price of 19.96 is below the 20-day moving average (MA) of 21.69, below the 50-day MA of 23.56, and above the 200-day MA of 19.91, indicating a neutral trend. The MACD of -1.22 indicates Positive momentum. The RSI at 34.00 is Neutral, neither overbought nor oversold. The STOCH value of 29.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	67 Neutral	$934.06M	―	-3.40%	―	22.68%	42.45%
TRVI	55 Neutral	$886.54M	―	-35.74%	―	―	-8.46%
VALN	55 Neutral	$777.31M	―	-36.50%	―	30.95%	-78.41%
Sector *	51 Neutral	$7.78B	-0.06	-40.08%	2.29%	21.32%	-1.82%
SVRA	46 Neutral	$542.71M	―	-99.30%	―	―	-21.05%
IMTX	45 Neutral	$635.71M	53.85	-17.34%	―	83.36%	22.27%
ANAB	40 Underperform	$562.74M	―	-343.83%	―	304.17%	29.37%

AnaptysBio Corporate Events

AnaptysBio Holds 2025 Annual Stockholders Meeting

On June 17, 2025, AnaptysBio, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were adopted. These included the election of three Class II directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the approval of amendments to the company’s 2017 Equity Incentive Plan. The meeting also featured non-binding advisory votes on executive compensation and the frequency of future advisory votes concerning executive compensation. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

AnaptysBio Reports Positive Phase 2b Trial Results

On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis. The trial demonstrated that rosnilimab achieved JAK-like efficacy with significant improvements in disease activity and remission rates, maintaining durable responses for at least two months off drug. The findings suggest rosnilimab’s potential for extended dosing intervals and its promising impact in the $20 billion U.S. RA market.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.